Calcium Channel Blockers Inhibit Pancreatic Neuroendocrine Neoplasms Progression via Cav1.2-Epigenetic Circuit

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Pancreatic neuroendocrine neoplasms (pNEN) are rare tumors with challenging treatment due to heterogeneity and poorly understood progression mechanisms.
• Disease progression often involves recurrence and metastasis, necessitating novel therapeutic strategies.

Purpose of the Study:

• To elucidate novel mechanisms driving pNEN progression.
• To investigate the role of Cav1.2 calcium signaling and H3K27 acetylation in pNEN.
• To evaluate the therapeutic potential of calcium channel blockers (CCBs) in pNEN.

Main Methods:

• Clinicomolecular analysis of pNEN samples.
• In vitro and in vivo studies using cell lines and animal models.
• Correlation analysis between CCB administration and patient outcomes (PFS, metastasis).

Main Results:

• A positive regulatory circuit between Cav1.2-mediated calcium signaling and H3K27 acetylation (H3K27ac) was identified.
• Tumor-cell-specific Cav1.2 expression correlates with pNEN progression and malignant behavior.
• CCBs, particularly amlodipine, inhibited pNEN progression in vitro and in vivo.
• Clinical CCB use was associated with improved progression-free survival and reduced metastasis.

Conclusions:

• The Cav1.2-epigenetic circuit represents a novel mechanism driving pNEN progression.
• CCBs offer a potential therapeutic avenue for pNEN, warranting further clinical investigation.
• Targeting this circuit could expand treatment strategies for pancreatic neuroendocrine neoplasms.